Attenuation of permeability lung injury after phorbol myristate acetate by verapamil and OKY-046.
D000179:Acrylates / Q000627:therapeutic use*; D000818:Animals; D002463:Cell Membrane Permeability / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D008168:Lung / Q000187:drug effects*; D008689:Methacrylates / Q000627:therapeutic use*; D011654:Pulmonary Edema / Q000139:chemically induced / Q000188:drug therapy; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D014700:Verapamil / Q000627:therapeutic use*
D000179:Acrylates; D008689:Methacrylates; D014700:Verapamil; D013930:Thromboxane-A Synthase; C034364:ozagrel; D013755:Tetradecanoylphorbol Acetate